This is a single-center intermediate expanded access program to provide access to the investigational product, CNM-Au8, up to 25 participants diagnosed with Multiple Sclerosis.
This is an intermediate expanded access program to provide access to the investigational product, CNM-Au8, for up to 25 participants. All participants will receive open label treatment with CNM-Au8 30 mg orally. The safety and efficacy of CNM-Au8 treatment in MS participants will be evaluated. Scheduled visits will occur at the baseline visit, week 6 visit, week 12, and then every 12-weeks thereafter at the participating clinic(s). Optional remote data collection via telemedicine and/or home healthcare visits are permitted commencing with the week 12 visit. Clinical safety laboratory monitoring including urinalysis, a chemistry panel (e.g., CMP) and a hematology panel (e.g., CBC) will be conducted at the screening/baseline visit and at each scheduled visit incorporating safety laboratory assessments. Participants who meet the inclusion criteria and none of the exclusionary criteria may be enrolled into the EAP. The program and participant visits will continue for a total of 96-weeks of treatment. Four weeks following treatment discontinuation, a safety follow-up visit will be conducted. Investigational product may be shipped by the site to participants who do not attend an in-clinic visit. The EAP may be discontinued at the Sponsor's sole discretion if: (i) there is insufficient funding to maintain the EAP, (ii) the Sponsor is unable to produce sufficient supply of the investigational product to meet clinical trial obligations, (iii) CNM-Au8 receives marketing authorization within the United States, or (iv) continued support of the EAP risks further clinical development of CNM-Au8.
Participants in the EAP must meet all the following inclusion criteria:
1. Able to understand and give written informed consent.
2. Male or female participants aged 18 years or greater (inclusive) at the time of
informed consent.
3. Participants with a neurologist confirmed diagnosis of MS per the 2017 McDonald
criteria of relapsing MS (RMS), non-active secondary progressive MS (NA-SPMS), or
primary progressive MS (PPMS).
4. Participant can consume up to 120 mL of the investigational drug suspension daily.
5. Participant is not adequately treated by current standard of care DMT, which is
evidenced by: progression independent of relapse activity (PIRA) based on an EDSS
change of 0.5 or more over a 6-month period where the initial EDSS was 4.0 or more,
OR an EDSS increase of 1.0 or more if over a 6-month period where the initial EDSS
was 2.0 or more, AND the participant has been treated with an MS immunomodulatory
disease modifying treatment (DMT) including S1P drugs (e.g., fingolimod, ponesimod,
ozanimod), natalizumab, cladribine, a B-cell depleting therapy (e.g., ocrelizumab,
ofatumumab), or other appropriate DMTs for at least the prior 6-months, OR has
demonstrated an EDSS increase per the criteria above despite at least a 6-month
period of prior immunomodulatory DMT treatment that was subsequently discontinued
due lack of response or intolerance to treatment.
6. Participant has an EDSS score of greater than or equal to 2.0 and less than or equal
to 6.5.
Participants may not be enrolled if they meet any of the following exclusion criteria:
1. A clinical relapse within the prior six months. NA-SPMS and PPMS participants may
not have had a history of gadolinium enhancing lesions within the prior 24-months.
2. History of significant major medical condition(s) that may interfere with the
conduct of the EAP or interpretation of the EAP results as determined by the
Investigator.
3. Based on the Investigator's judgment, participants who may have difficulty complying
with the protocol and/or study procedures.
4. History of any clinically significant abnormality in hematology, blood chemistry,
ECG, or physical examination not resolved by the Screening/Baseline visit.
5. Participant has clinically significant findings at the Screening/Baseline visit on
standard hepatic, hematologic, or renal safety assays, including but not limited to:
(i) ALT or AST ≥ 3 times upper limits of normal, (ii) direct (conjugated) with
bilirubin ≥2 times upper limits of normal, (iii) Child-Pugh Classification B
(moderate) or C (severe), (iv) low platelet counts (< 150 x 109 per liter), (v)
eosinophilia (absolute eosinophil count of ≥ 500 eosinophils per microliter), (vi)
serum creatinine >1.2 mg/dL, or (vii) eGFR < 45 ml/min per 1.73 m2.
6. Females who are pregnant, have a positive pregnancy test, are nursing, or who plan
to get pregnant during participation in the EAP or within 6 months of the ending
participation in the EAP.
7. Women of child-bearing potential, or men, who are unwilling or unable to use
accepted methods of birth control during the study and for 6 months following
completion of study participation.
8. Participants with a history of gold allergy.
9. Participant is considered a suicide risk in the opinion of the Investigator, has
previously made a suicide attempt, or is currently demonstrating any active or
intermittent suicidal ideation.
10. Participants with a history of any of the following: a. History of human
immunodeficiency virus (HIV), hepatitis C (HepC) virus antibody, or hepatitis B
(HepB) virus antibody without history of previous HepB vaccination. b. History or
evidence of substance abuse or alcohol abuse within 5- years prior to Screening,
including alcoholism; or severe tobacco use (>1 pack/day). c. Any history of
previous malignancy, with the exception of basal cell carcinoma of the skin or in
situ carcinoma of the cervix, post documented full resections, with clean margins.
11. Current treatment with immunosuppressive or immunomodulatory therapy other than
those approved for the treatment of MS.